The use of trilostane for the treatment of alopecia X in Alaskan malamutes.
Three Alaskan malamutes with hair loss and slightly elevated blood concentrations of 17-hydroxyprogesterone after stimulation with adrenocorticotropic hormone (ACTH) were treated with trilostane. Trilostane, an inhibitor of 3 beta-hydroxysteroid dehydrogenase, was given twice daily at a dose of 3.0 to 3.6 mg/kg per day orally for 4 to 6 months. Routine ACTH stimulation tests were performed over 8 months to evaluate the degree of adrenal function suppression. Treatment with trilostane led to complete hair regrowth in all three dogs within 6 months. No adverse effects associated with trilostane were recognized.
Leone
F
F
Clinica Veterinaria Adriatica, Senigallia, Senigallia, Italy.
Cerundolo
R
R
Vercelli
A
A
Lloyd
D H
DH
D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D000324:Adrenocorticotropic Hormone; D000505:Alopecia / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D000818:Animals; D013196:Dihydrotestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000201:enzymology; D004285:Dogs; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D019326:17-alpha-Hydroxyprogesterone; D000324:Adrenocorticotropic Hormone; D015096:3-Hydroxysteroid Dehydrogenases; C009954:trilostane